-
公开(公告)号：US11247989B2
公开(公告)日：2022-02-15
申请号：US16198581
申请日：2018-11-21
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Patrick Cyr , Sarah Bronner , F. Anthony Romero , Steven Magnuson , Vickie Hsiao-Wei Tsui , Jeremy M. Murray , John Wai , Kwong Wah Lai , Fei Wang , Kevin X. Chen
IPC: C07D471/04 , C07D519/00
Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US11168070B2
公开(公告)日：2021-11-09
申请号：US16886541
申请日：2020-05-28
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Patrick Cyr , Sarah Bronner , F. Anthony Romero , Steven Magnuson , Vickie Hsiao-Wei Tsui , John Wai , Kwong Wah Lai , Fei Wang
IPC: C07D401/04 , A61K31/47 , A61P25/00 , C07D401/14 , C07D405/14 , C07D413/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D243/14 , C07D413/04 , C07D267/14 , C07D413/10 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/5513 , A61K45/06 , C07D487/22
Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US10696655B2
公开(公告)日：2020-06-30
申请号：US16198597
申请日：2018-11-21
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Patrick Cyr , Sarah Bronner , F. Anthony Romero , Steven Magnuson , Vickie Hsiao-Wei Tsui , John Wai , Kwong Wah Lai , Fei Wang
IPC: C07D223/16 , C07D243/12 , C07D243/14 , C07D267/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/04 , C07D417/14 , C07D401/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D413/10 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/5513 , A61K45/06 , C07D487/22
Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US20180022727A1
公开(公告)日：2018-01-25
申请号：US15643808
申请日：2017-07-07
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Brian K. Albrecht , Alexandre Cote , Victor Gehling , Vickie Hsiao-Wei Tsui , James Richard Jr. Kiefer , Jun Liang , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , F. Anthony Romero , Alexander M. Taylor , Birong Zhang
IPC: C07D401/06 , C07D241/04 , C07D211/30 , C07D413/06
CPC classification number: C07D401/06 , C07D211/30 , C07D241/04 , C07D405/06 , C07D409/06 , C07D413/06
Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号：US20170333406A1
公开(公告)日：2017-11-23
申请号：US15667227
申请日：2017-08-02
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Marc Adler , Brian K. Albrecht , Sarah Bronner , Kevin X. Chen , Alexandre Côté , Terry Crawford , Patrick Cyr , Jackson Egen , Steven Kauder , Kwong Wah Lai , Jiangpeng Liao , Steven Magnuson , Jeremy Murray , Richard Pastor , F. Anthony Romero , Alexander M. Taylor , Vickie Hsiao-Wei Tsui , Fei Wang , Bing-Yan Zhu
IPC: A61K31/437 , C07D471/04 , A61K45/06 , A61K31/55 , A61K31/5415 , A61K31/5377 , A61K31/4375 , A61K31/506 , A61K31/498 , A61K31/496 , A61K31/4725 , A61K31/4709 , C07D519/00 , A61K31/538
CPC classification number: A61K31/437 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5415 , A61K31/55 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
Patent Agency Ranking
公开(公告)号：US20160158207A1
公开(公告)日：2016-06-09
申请号：US14952821
申请日：2015-11-25
Applicant: Constellation Pharmaceuticals, Inc. , Genentech, Inc.
Inventor： Marc Adler , Brian K. Albrecht , Sarah Bronner , Kevin X. Chen , Alexandre Côté , Terry Crawford , Patrick Cyr , Jackson Egen , Steven Kauder , Kwong Wah Lai , Jiangpeng Liao , Steven Magnuson , Jeremy Murray , Richard Pastor , F. Anthony Romero , Alexander M. Taylor , Vickie Hsiao-Wei Tsui , Fei Wang , Bing-Yan Zhu
IPC: A61K31/437 , A61K31/538 , A61K31/5415 , A61K31/4709 , A61K31/498 , A61K45/06 , A61K31/55 , C07D519/00 , A61K31/4375 , A61K31/4725 , A61K31/496 , A61K31/5377 , C07D471/04 , A61K31/506
CPC classification number: A61K31/437 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5415 , A61K31/55 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
Abstract translation: 本发明涉及式（I）或式（II）化合物及其盐，其中式（I）的R 1 -R 4和式（II）的R 1 -R 3具有本文定义的任何值，组合物 及其用途。 该化合物可用作CBP和/或EP300的抑制剂。 还包括包含式（II）的式（I）化合物或其药学上可接受的盐的药物组合物，以及在治疗各种CBP和/或EP300介导的病症中使用这些化合物和盐的方法。
-
7.发明申请公开(公告)号：US20160024504A1
公开(公告)日：2016-01-28
申请号：US14776051
申请日：2014-03-14
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Benjamin Fauber , Hon-Ren Huang , Jose M. Lora , Steven Magnuson , Christopher G. Nasveschuk , Andres Salmeron , Robert J. Sims, III , Alexander M. Taylor
IPC: C12N15/113 , G01N33/50 , A61K31/444 , A61K31/437 , A61K31/496
CPC classification number: C12N15/113 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/713 , C07K14/4702 , C12N2310/14 , C12N2320/30 , G01N33/505 , G01N2333/52 , G01N2500/04 , G01N2500/10 , Y02A50/422
Abstract: The invention provides methods for treating Th2 cytokine-mediated diseases by inhibiting bromodomain function.
Abstract translation: 本发明提供了通过抑制溴结构域功能来治疗Th2细胞因子介导的疾病的方法。
-
公开(公告)号：US10155764B2
公开(公告)日：2018-12-18
申请号：US15449692
申请日：2017-03-03
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , Anthony F. Romero , Alexander M. Taylor
IPC: C07D487/04 , C07D403/12 , C07D401/12 , C07D237/32 , C07D471/04 , A61K31/502 , A61K31/5025 , A61K31/5377 , A61K31/55 , C07D237/34 , C07D405/12
Abstract: The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20170334883A1
公开(公告)日：2017-11-23
申请号：US15449706
申请日：2017-03-03
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , Anthony F. Romero , Alexander M. Taylor
IPC: C07D403/12 , C07D401/12 , C07D401/04 , C07D253/075 , A61K45/06 , C07D403/04 , A61K31/53
CPC classification number: C07D403/12 , A61K31/53 , A61K45/06 , A61P35/00 , C07D249/12 , C07D253/075 , C07D401/04 , C07D401/12 , C07D403/04
Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10316023B2
公开(公告)日：2019-06-11
申请号：US15449706
申请日：2017-03-03
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , F. Anthony Romero , Alexander M. Taylor
IPC: C07D249/12 , C07D403/04 , C07D403/12 , C07D401/04 , C07D401/12 , A61K31/53 , A61K31/4196 , A61P35/00 , C07D253/075 , A61K45/06
Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.094 seconds)
